Entera Bio - ENTX Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entera Bio in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ENTX shares.
View ENTX analyst ratings or view top-rated stocks.

2 equities research analysts have issued 1 year target prices for Entera Bio's shares. Their ENTX share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for ENTX or view top-rated stocks among Wall Street analysts.

Entera Bio's stock was trading at $0.73 at the beginning of the year. Since then, ENTX stock has increased by 43.8% and is now trading at $1.05.
View the best growth stocks for 2023 here.

Entera Bio saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 86,700 shares, an increase of 181.5% from the February 13th total of 30,800 shares. Based on an average daily volume of 219,900 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.4% of the shares of the company are sold short.
View Entera Bio's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our ENTX earnings forecast.

Entera Bio Ltd. (NASDAQ:ENTX) released its quarterly earnings results on Thursday, November, 11th. The company reported ($0.09) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.03. The firm had revenue of $0.14 million for the quarter. Entera Bio had a negative trailing twelve-month return on equity of 27.72% and a negative net margin of 1,796.49%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Entera Bio investors own include Fulcrum Therapeutics (FULC), Cara Therapeutics (CARA), Gilead Sciences (GILD), Supernus Pharmaceuticals (SUPN), VIVUS (VVUS), Vaxart (VXRT), AbbVie (ABBV), Acasti Pharma (ACST) and Allena Pharmaceuticals (ALNA).

(ENTX) raised $11 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 1,400,000 shares at $8.00 per share. Maxim Group served as the underwriter for the IPO and Joseph Gunnar was co-manager.

Entera Bio trades on the NASDAQ under the ticker symbol "ENTX."

Entera Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (1.03%), Renaissance Technologies LLC (0.48%) and Millennium Management LLC (0.16%). Insiders that own company stock include Miranda Jayne Toledano, Ramesh Ratan, Ron Mayron, Sean Ellis and Yonatan Malca.
View institutional ownership trends.

Shares of ENTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ENTX stock can currently be purchased for approximately $1.05.

Entera Bio (NASDAQ:ENTX) has a market capitalization of $30.24 million and generates $570,000.00 in revenue each year. The company earns $-12,190,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis.

Entera Bio's mailing address is FIFTH FLOOR KIRYAT HADASSAH MINRAV BUILDING, JERUSALEM L3, 9112002. The official website for the company is www.enterabio.com. The company can be reached via phone at (722) 532-7151 or via email at investorrelations@enterabio.com.